Whole prostate D90 and V100: A dose–response analysis of 2000 consecutive 125I monotherapy patients-Reference-Cited by-同舟云学术

Whole prostate D90 and V100: A dose–response analysis of 2000 consecutive 125I monotherapy patients

Published:2014-01 Issue:1 Volume:13 Page:32-41
ISSN:1538-4721
Container-title:Brachytherapy
language:en
Short-container-title:Brachytherapy

Author:

Morris W. James,Spadinger Ingrid,Keyes Mira,Hamm Jeremy,McKenzie Michael,Pickles Tom

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Reference27 articles.

1. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group;Grimm;BJU Int,2012

2. Counterpoint: There is a dose-response relationship in the low-dose rate brachytherapy management of prostate cancer;Stock;Brachytherapy,2010

3. Evaluation of dosimetric parameters and disease response after 125 iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer;Morris;Int J Radiat Oncol Biol Phys,2009

4. Outcomes following iodine-125 brachytherapy in patients with Gleason 7, intermediate risk prostate cancer: A population-based cohort study;Herbert;Radiother Oncol,2012

5. Whole prostate D90 and V100 are weak predictors of biochemical relapse in 1500 consecutive low dose rate (LDR) brachytherapy implants for low and intermediate risk prostate cancer;Morris;Radiother Oncol,2010

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic prostate cancer interventions: a systematic review on pubic arch interference and needle positioning errors;Expert Review of Medical Devices;2024-07-02

2. Uncertainty in magnetic resonance imaging-based prostate postimplant dosimetry: Results of a 10-person human observer study, and comparisons with automatic postimplant dosimetry;Brachytherapy;2023-11

3. After ASCENDE-RT: Biochemical and survival outcomes following combined external beam radiotherapy and low-dose-rate brachytherapy for high-risk and unfavourable intermediate-risk prostate cancer, a population-based analysis;Brachytherapy;2022-09

4. Dosimetric outcomes of preoperative treatment planning with intraoperative optimization using stranded seeds in prostate brachytherapy;PLOS ONE;2022-03-30

5. MRI-defined treatment margins, urinary toxicity, and PSA response in LDR prostate brachytherapy;Brachytherapy;2022-03